
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3828952/publications.pdf Version: 2024-02-01



KDISTI RAKED

#	Article	IF	CITATIONS
1	Isolation of endogenous cytosolic DNA from cultured cells. STAR Protocols, 2022, 3, 101165.	0.5	3
2	Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN–driven CCL5 and CXCL10. Journal of Experimental Medicine, 2021, 218, .	4.2	61
3	FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex–driven autoimmunity. Journal of Experimental Medicine, 2020, 217, .	4.2	24
4	Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trial. BMJ Open, 2019, 9, e030502.	0.8	15
5	Organoids Provide an Important Window on Inflammation in Cancer. Cancers, 2018, 10, 151.	1.7	27
6	Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns. American Journal of Reproductive Immunology, 2018, 80, e12972.	1.2	47
7	Neonatal FC Receptor Cooperates with Classical FC Gamma Receptors to Control Inflammatory Bowel Disease through Regulating Immune Complex Processing. Gastroenterology, 2017, 152, S614.	0.6	0
8	Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2862-E2871.	3.3	84
9	A simple, cost-effective method for generating murine colonic 3D enteroids and 2D monolayers for studies of primary epithelial cell function. American Journal of Physiology - Renal Physiology, 2017, 313, G467-G475.	1.6	34
10	Bacteriophage Transcytosis Provides a Mechanism To Cross Epithelial Cell Layers. MBio, 2017, 8, .	1.8	273
11	A Critical Review on the Effect of Docosahexaenoic Acid (DHA) on Cancer Cell Cycle Progression. International Journal of Molecular Sciences, 2017, 18, 1784.	1.8	86
12	Immunoglobulin Transport and Immunoglobulin Receptors. , 2015, , 349-407.		12
13	lgE/FcεRI-Mediated Antigen Cross-Presentation by Dendritic Cells Enhances Anti-Tumor Immune Responses. Cell Reports, 2015, 10, 1487-1495.	2.9	61
14	A homozygousPMS2founder mutation with an attenuated constitutional mismatch repair deficiency phenotype. Journal of Medical Genetics, 2015, 52, 348-352.	1.5	30
15	FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. Journal of Immunology, 2015, 194, 4595-4603.	0.4	199
16	Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Critical Reviews in Biotechnology, 2015, 35, 235-254.	5.1	201
17	Neonatal Fc receptors for IgG drive CD8+T cell-mediated anti-cancer immunosurveillance at tolerogenic mucosal sites. Oncolmmunology, 2014, 3, e27844.	2.1	2
18	The Role of FcRn in Antigen Presentation. Frontiers in Immunology, 2014, 5, 408.	2.2	88

#	Article	IF	CITATIONS
19	Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature, 2014, 509, 497-502.	13.7	172
20	Regulation of Immune Responses by the Neonatal Fc Receptor and Its Therapeutic Implications. Frontiers in Immunology, 2014, 5, 664.	2.2	47
21	Cross-presentation of IgG-containing immune complexes. Cellular and Molecular Life Sciences, 2013, 70, 1319-1334.	2.4	28
22	The Immunologic Functions of the Neonatal Fc Receptor for IgG. Journal of Clinical Immunology, 2013, 33, 9-17.	2.0	120
23	Regulation of Immunological Responses by the Neonatal Fc Receptor for IgG, FcRn. , 2013, , 189-219.		0
24	Neonatal Fc Receptor Expression in Dendritic Cells Mediates Protective Immunity against Colorectal Cancer. Immunity, 2013, 39, 1095-1107.	6.6	112
25	<scp>CEACAM</scp> 1 on activated <scp>NK</scp> cells inhibits <scp>NKG</scp> 2 <scp>D</scp> â€mediated cytolytic function and signaling. European Journal of Immunology, 2013, 43, 2473-2483.	1.6	44
26	Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status. Journal of Clinical Pathology, 2012, 65, 996-1002.	1.0	36
27	The Short Isoform of the CEACAM1 Receptor in Intestinal T Cells Regulates Mucosal Immunity and Homeostasis via Tfh Cell Induction. Immunity, 2012, 37, 930-946.	6.6	40
28	Biology of Gut Immunoglobulins. , 2012, , 1089-1118.		1
29	Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology, 2011, 58, no-no.	1.6	104
30	Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology, 2011, 59, 482-495.	1.6	37
31	CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells. Journal of Experimental Medicine, 2011, 208, 2633-2640.	4.2	64
32	Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8 ^{â^'} CD11b ⁺ dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9927-9932.	3.3	187
33	Neonatal Fc Receptor: From Immunity to Therapeutics. Journal of Clinical Immunology, 2010, 30, 777-789.	2.0	208
34	Vavâ€1 expression correlates with NFκB activation and CD40â€mediated cell death in diffuse large Bâ€cell lymphoma cell lines. Hematological Oncology, 2010, 28, 142-150.	0.8	11
35	Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma. Leukemia Research, 2010, 34, 585-593.	0.4	13
36	TIA-1 Cytotoxic Granule-Associated RNA Binding Protein Improves the Prognostic Performance of CD8 in Mismatch Repair-Proficient Colorectal Cancer. PLoS ONE, 2010, 5, e14282.	1.1	52

#	Article	IF	CITATIONS
37	Beyond IgA: the mucosal immunoglobulin alphabet. Mucosal Immunology, 2010, 3, 324-325.	2.7	10
38	Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Human Pathology, 2010, 41, 70-78.	1.1	24
39	Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups. Cancer, 2009, 115, 4021-4029.	2.0	46
40	MSI-H colorectal cancers preferentially retain and expand intraepithelial lymphocytes rather than peripherally derived CD8+ T cells. Cancer Immunology, Immunotherapy, 2009, 58, 135-144.	2.0	10
41	Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Seminars in Immunopathology, 2009, 31, 223-236.	2.8	115
42	An FcRn-Dependent Role for Anti-flagellin Immunoglobulin G in Pathogenesis of Colitis in Mice. Gastroenterology, 2009, 137, 1746-1756.e1.	0.6	77
43	Colorectal cancer cells express functional cell surfaceâ€bound TGFβ. International Journal of Cancer, 2008, 122, 1695-1700.	2.3	6
44	Multimarker phenotype predicts adverse survival in patients with lymph nodeâ€negative colorectal cancer. Cancer, 2008, 112, 495-502.	2.0	58
45	Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. British Journal of Cancer, 2008, 99, 1712-1717.	2.9	37
46	Node-Negative Colorectal Cancer at High Risk of Distant Metastasis Identified by Combined Analysis of Lymph Node Status, Vascular Invasion, and Raf-1 Kinase Inhibitor Protein Expression. Clinical Cancer Research, 2008, 14, 143-148.	3.2	69
47	RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis. Clinical Cancer Research, 2008, 14, 3798-3806.	3.2	46
48	Loss of Raf-1 Kinase Inhibitor Protein Expression Is Associated With Tumor Progression and Metastasis in Colorectal Cancer. American Journal of Clinical Pathology, 2007, 127, 820-827.	0.4	119
49	Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: A potential role for dysregulation of the transforming growth factor-12 pathway. European Journal of Cancer, 2007, 43, 624-631.	1.3	57
50	Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. European Journal of Cancer, 2007, 43, 1101-1107.	1.3	60
51	Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Modern Pathology, 2007, 20, 331-338.	2.9	69
52	Prognostic significance of the wnt signalling pathway molecules APC, ?-catenin and E-cadherin in colorectal cancer?a tissue microarray-based analysis. Histopathology, 2007, 50, 453-464.	1.6	118
53	Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal–regulated kinase, and phosphorylated AKT in colorectal cancer—A tissue microarray–based approachâ~†. Human Pathology, 2006, 37, 1022-1031.	1.1	40
54	Granuloma annulare associated with hypercalcemia secondary to hyperparathyroidism. International Journal of Dermatology, 2006, 45, 1118-1120.	0.5	6

#	Article	IF	CITATIONS
55	Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. Histopathology, 2006, 49, 121-131.	1.6	230
56	Transforming growth factor-beta pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. Histopathology, 2006, 49, 371-380.	1.6	14
57	Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Modern Pathology, 2006, 19, 1302-1309.	2.9	51
58	Tumor Buds Show Reduced Expression of Laminin-5 Gamma 2 Chain in DNA Mismatch Repair Deficient Colorectal Cancer. Diseases of the Colon and Rectum, 2006, 49, 1193-1202.	0.7	17
59	Hyperplastic polyposis and cancer of the colon with gastrinoma of the duodenum. Nature Clinical Practice Oncology, 2006, 3, 281-284.	4.3	9
60	Linear Lichen Planopilaris of the Trunk: First Report of a Case. Journal of Cutaneous Medicine and Surgery, 2006, 10, 136-138.	0.6	18
61	Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut, 2006, 55, 1467-1474.	6.1	131